

Symbiox Investment & Trading Co. Ltd.

221, Rabindra Sarani, 3rd Floor
Room No. - 1, Kolkata - 700 007
Contact : 98302 74227
CIN : L65993WB1979PLC032012
Website : www.symbioxinvestment.com
E-mail : symbioxinvestment100@gmail.com

Date: 29st May, 2023

To, Compliance Department Metropolitan Stock Exchange of India Limited Vibgyor Towers, 4th floor, Plot No C 62, G - Block, Opp. Trident Hotel, Bandra Kurla Complex, Bandra (E), Mumbai – 400 098	To, The Calcutta Stock Exchange Limited 7, Lyons Range, Kolkata- 700 001	To, The Bombay Stock Exchange Limited, PJ Towers, Dalal Street Mumbai- 400 001
---	--	--

Sub: Audited Financial result for the quarter and year ended 31.03.2023

BSE Scrip Code: 539278 CSE Scrip Code: 029461 Symbol: SYMBIOX

Dear Sir,


This is to inform you that Pursuant to Regulation 33 of SEBI (Listing Obligation & Disclosure Requirement) Regulation 2015, the Board of Directors of the company at their meeting held on 29th May, 2023, have approved the Audited Financial Results of the company for the quarter and Year ended 31th March, 2023.


1. Approved the Audited Financial Results (Standalone) for the Quarter and year ended on 31th March, 2023 as recommended by the Audit committee.
2. Auditor's Limited Review Report in the prescribed format issued by the Statutory Auditor of the Company also attached herewith.
3. Declaration for unmodified audit report in respect of Standalone financial statements for the year 2022-2023 under SEBI (Listing Obligations and Disclosure Requirement) Regulations, 2015

Please take the same on your record and acknowledge the receipt of the same.

Thanking You.
Yours Faithfully,

For Symbiox Investment & Trading Co Ltd


SAMIT RAY
Director
DIN No: 08406285





Head Office :- Office No.215, 2nd Floor, Gundecha Ind. Estate, Akurli Road, Kandivali (E), Mumbai - 400 101.
Tel : +91 22-67337024 / +91 22-67337025 | Email : ssrvandassociates@gmail.com

INDEPENDENT AUDITORS' REPORT

TO THE BOARD OF DIRECTORS OF SYMBIOX INVESTMENT & TRADING CO LTD

Report on the audit of the Standalone Annual Financial Results

Opinion

We have audited the accompanying standalone annual financial results of **Symbiox Investment & Trading Co Ltd** ("the Company") for the quarter and year ended 31st March, 2023, attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us these standalone annual financial results:

- i. are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
- ii. give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable accounting standards and other accounting principles generally accepted in India of the net profit/loss and other comprehensive income and other financial information for the year ended 31st March, 2023.


Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013 (the Act). Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Standalone Financial Results section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial results under the provisions of the Companies Act, 2013 and the Rules there under, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Management's Responsibilities for the Standalone Financial Results

These standalone annual financial results have been prepared on the basis of the standalone annual financial statements. The Company's Board of Directors are responsible for the preparation of these financial results that give a true and fair view of the net profit/ loss and other comprehensive income and other financial information in accordance with the recognition and measurement principles laid down in applicable Indian Accounting Standards prescribed under Section 133 of the Act read with relevant rules issued there under and other accounting principles generally accepted in India and in, compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the

UDIN : 23403437BGWDHV7140



provisions of the Act , for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the standalone financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the standalone annual financial results, the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to, cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the Company's financial Reporting process.

Auditor's Responsibilities for the Audit of the Standalone Financial Results

v. Evaluate the overall presentation, structure and content of the standalone annual financial results, including the disclosures, and whether the financial results represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Other matter

The standalone annual financial results include the results for the quarter ended 31st March, 2023 and the corresponding quarter ended in the previous year being the balancing figure between the audited figures in respect of the full financial year and the published unaudited year to date figures up to the third quarter of the relevant financial year which were subject to limited review by us.

For S S R V & Associates

(Chartered Accountants)

FRN No.: 135901W


Vishnu Kant Kabra
Vishnu Kant Kabra

(Partner)
(Partner)

Mem No.: 403437

Date.: 29th May, 2023

Place.: Mumbai



UDIN .: 23403437BGWDHV7140

SYMBIOX INVESTMENT & TRADING CO LTD
221, RABINDRA SARANI, 3RD FLOOR, ROOM NO-1, KOLKATA -700007.
CIN - L65993WB1979PLC032012
Email - symbioxinvestment100@gmail.com; Website: www.symbioxinvestment.com

Audited Standalone Statement of Assets & Liabilities as on 31st March, 2023.

(Rs. In Lakh)

Standalone Statement of Assets and Liabilities		As at 31st March 2023	As at 31st March 2022
Particulars		(Audited)	(Audited)
A ASSEST			
1 Non-current assets			
(a) Property, plant and equipment		0.38	0.38
(b) Capital work-in -progress		-	-
(c) Goodwill		-	-
(c) other Intangible assets		-	-
(d) Intangible assets under development		-	-
(e) Investments in subsidiary, joint ventures and associate		-	-
(f) Non- current Financial Assets		-	-
(i) Non-current Investments		-	-
(ii) Non-current Trade receivables		-	-
(iii) Non-current Loans		-	-
(iv) Other Non-current financial assests		-	-
Total non-current financial assets		0.38	0.38
(g) Defferred tax assets (net)		-	-
(h) Other non-current assets		-	-
Total non-current assets		0.38	0.38
2 Current Assets			
(a) Inventories		20.80	-
(b) Current financial assets		-	-
(i) Current Investments		1,272.23	1,754.44
(ii) Trade receivables		79.73	86.75
(iii) Cash and cash equivalents		0.92	11.19
(iv) Bank Balance other than cash and cahs equivalents		53.29	11.64
(v) Current Loans		1,840.08	1,307.85
(vi) Other corrent financial assets		8.82	8.89
Total current financial assets		3,275.87	3,180.76
(c) Current tax assets (net)		-	-
(d) Other current financial assets		-	-
Total Current assets		3,275.87	3,180.76
Non-current assets classified as held for sale Regulatory deferral			
3 account debit balance and related deferred tax Assets		-	-
Total Assets		3,276.25	3,181.14



B	EQUITY AND LIABILITIES		
1	EQUITY		
	Equity attributable to owner of parent	-	-
	(a) Equity share Capital	3,128.73	3,128.73
	(b) Other equity	3.65	-12.04
	Total Equity attributable to owner of parent	3,132.38	3,116.69
	(c) Non controlling interest	-	-
	Total Equity	3,132.38	3,116.69
2	LIABILITIES		
	Non-current liabilites		
	(a) Non-current financial liabilites		
	(i) Borrowings	-	-
	(ii) Trade Payables	-	-
	(iii) Other non-current financial liabilities	-	-

SYMBIOX INVESTMENT & TRADING CO LTD 221, RABINDRA SARANI, 3RD FLOOR, ROOM NO-1, KOLKATA -700007. CIN - L65993WB1979PLC032012 Email - symbioxinvestment100@gmail.com; Website: www. symbioxinvestment.com					
Standalone Statement of Audited Financial Result for the year ended 31st March, 2023. (Rupees in Lakh except EPS)					
Particulars	Quarter ended			Year ended	
	31-03-2023	31-12-2022	31-03-2022	31-03-2023	31-03-2022
	Audited	Unaudited	Audited	Audited	Audited
I Revenue From Operations	-14.68	48.96	46.00	398.24	105.28
II Other Income	1.64	0.00	-11.89	1.64	71.81
III Total Income (I+II)	-13.04	48.96	34.11	399.88	177.09
IV EXPENSES					
Cost of materials consumed	-	-	-	0.00	-
Purchases of Stock-in-Trade	46.47	42.50	51.41	343.97	109.47
Changes in Inventories of finished goods, Stock-in -Trade and work-in-progress	-20.80	0.00	0.00	-20.80	0.00
Employee benefits expense	8.35	0.75	7.75	19.22	16.30
Finance costs	-	-	-	0.00	-
Depreciation and amortization expense	0.00	0.00	0.00	0.00	0.00
Other expenses	22.53	2.78	5.77	35.94	32.55
Total expenses (IV)	56.55	46.03	64.93	378.33	158.32
V Profit/(loss) before exceptional items and tax (I- IV)	-69.59	2.93	-30.82	21.55	18.77
VI Exceptional Items	-	-	-	0.00	-
VII Profit/(loss) before tax (V-VI)	-69.59	2.93	-30.82	21.55	18.77
VIII Tax expense:					
(1) Current tax	-18.06	2.68	-7.57	5.64	4.88
(2) Deferred tax	-	-	-	0.00	-
IX Profit (Loss) for the period from continuing operations (VII-VIII)	-87.65	0.25	-23.25	15.91	13.89
X Profit/(loss) from discontinued operations	-	-	-	0.00	-
XI Tax expense of discontinued operations	-	-	-	0.00	-
XII Profit/(loss) from Discontinued operations (after tax) (X-XI)	-87.65	0.25	-23.25	15.91	13.89
XIII Profit/(loss) for the period (IX+XII)	-87.65	0.25	-23.25	15.91	13.89
XIV Other Comprehensive Income					
A (i) Items that will not be reclassified to profit or loss	-	-	-	-	-
(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-
B (i) Items that will be reclassified to profit or loss	-	-	-	-	-
(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-

	Paid up equity share Capital (No. of Shares)	31287330	31287330	31287330	31287330	31287330
	Face Value	10.00	10.00	10.00	10.00	10.00
XVI	Earnings per equity share (for continuing operation):					
	(1) Basic	-0.280	0.0008	-0.074	0.051	0.044
	(2) Diluted	-0.280	0.0008	-0.074	0.051	0.044
XVII	Earnings per equity share (for discontinued operation):					
	(1) Basic	0.000	0.000	0.000	0.000	0.000
	(2) Diluted	0.000	0.000	0.000	0.000	0.000
XVIII	Earnings per equity share (for discontinued & continuing operations)					
	(1) Basic	0.000	0.000	0.000	0.000	0.000


SYMBIOX INVESTMENT & TRADING CO LTD
221, RABINDRA SARANI, 3RD FLOOR, ROOM NO-1, KOLKATA -700007.
CIN - L65993WB1979PLC032012
Email - symbioxinvestment100@gmail.com; Website: www. symbioxinvestment.com

Cash Flow Standalone Statement for the period ended as on 31st March, 2023.

	For the year ended 31st March 2023 (Rupees in lakh)	For the year ended 31st March 2022 (Rupees in lakh)
<u>CASH FLOW FROM OPERATING ACTIVITIES</u>		
Net profit before tax and after extra- ordinary items (As per profit & loss account)	21.55	18.77
Adjustments for items not included	-0.22	-
Operating Profit before working capital changes	21.33	18.77
<u>Working capital adjustments: -</u>		
(Increase)/ decrease in current loans and advances	-528.31	195.39
(Increase)/ decrease in Trade receivables	7.02	-86.72
(Increase)/ decrease in current assets	-20.81	-
Increase/ (decrease) in Trade Payable	73.52	-159.08
Increase/ (decrease) in current liabilities	4.89	-1.02
Cash generated from operations	-442.36	-32.66
Direct Taxes Paid(Net of refund)	4.88	2.44
Net cash flow from operating activities (A)	-447.24	-35.10
<u>CASH FLOW FROM INVESTING ACTIVITIES</u>		
Proceed from sale(purchase) of investments	482.21	39.55
(Increase)/decrease in capital expenditure	-	-
(Increase)/decrease in fixed assets	-	-
Net cash flow from investing activities (B)	482.21	39.55
<u>CASH FLOW FROM FINANCING ACTIVITIES</u>		
Proceeds from issue of equity shares	-	-
Share Application Money received(refund)	-	-
Net cash flow from financing activities (C)	-	-
Net cash flow during the year (A + B + C)	34.97	4.45
Add: Opening cash and cash equivalents	19.24	14.79
Closing cash and cash equivalents	54.21	19.24
Components of cash and cash equivalents		
Cash in hand	0.92	7.59
Deposit with banks in current accounts	53.29	11.65
Toal cash and cash equivalents	54.21	19.24

For and behalf of Board SYMBIOX INVESTMENT & TRADING CO LTD

Place: Mumbai
Date: 29.05.2023



Mina Agarwal
Mina Devi Agarwal
Director
DIN No. 07370734
Kolkata

Symbiox Investment & Trading Co. Ltd.

221, Rabindra Sarani, 3rd Floor
Room No. - 1, Kolkata - 700 007
Contact : 98302 74227
CIN : L65993WB1979PLC032012
Website : www.symbioxinvestment.com
E-mail : symbioxinvestment100@gmail.com

Date: 29th May, 2023

To,
Compliance Department
Metropolitan Stock Exchange of India Limited
Vibgyor Towers, 4th floor, Plot No C 62, G - Block
Opp. Trident Hotel, Bandra Kurla Complex,
Bandra (E),
Mumbai - 400 098

To,
The Calcutta Stock Exchange Limited
7, Lyons Range,
Kolkata- 700 001

To,
The Bombay Stock Exchange Limited,
PJ Towers, Dalal Street
Mumbai- 400 001

Ref: SEIB Circular No. CIR/CFD/CMD/56/2016 dated 27th May, 2016.

Sub: Declaration pursuant to Regulation 33(3)(d) of the Securities & Exchange Board of India (Listing Obligation and Disclosure Requirements) Regulations, 2015 ["LODR"].

Sir/ Madam,

In compliance with Regulation 33(3)(d) of LODR as amended by SEBI Circular No.

CIR/CFD/CMD/56/2016 dated 27 May 2016.